Filing Details
- Accession Number:
- 0000078003-23-000011
- Form Type:
- 13G Filing
- Publication Date:
- 2023-02-12 19:00:00
- Filed By:
- Pfizer Inc
- Company:
- An2 Therapeutics Inc.
- Filing Date:
- 2023-02-13
- SEC Url:
- 13G Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| (VOLUNTARY) Pfizer Inc. 13-5315170 | 0 | 1,362,499 | 0 | 1,362,499 | 1,362,499 | 7.02% |
| (VOLUNTARY) Anacor Pharmaceuticals | 0 | 1,362,499 | 0 | 1,362,499 | 1,362,499 | 7.02% |
Filing
CUSIP No. 037326105
| SECURITIES AND EXCHANGE COMMISSION | ||
| Washington, D.C. 20549 | ||
| SCHEDULE 13G | ||
| (Rule 13d-102) | ||
| INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT | ||
| TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED | ||
| PURSUANT TO RULE 13d-2(b) | ||
(Amendment No. ) 1 | ||
| AN2 THERAPEUTICS, INC. | ||
| (Name of Issuer) | ||
| Common Stock, $0.00001 par value per share | ||
| (Title of Class of Securities) | ||
| 037326105 | ||
| (CUSIP Number) | ||
| December 31, 2022 | ||
| (Date of Event Which Requires Filing of this Statement) | ||
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
__________
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
Page 1 of 8
CUSIP No. 037326105
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY) Pfizer Inc. 13-5315170 | |||||||||||||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ] (b) [ ] | ||||||||||||
| 3. | SEC USE ONLY | |||||||||||||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||||||||||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER -0- | ||||||||||||
| 6. | SHARED VOTING POWER 1,362,499 shares of Common Stock, $0.00001 par value per share ("Common Stock") held by Anacor Pharmaceuticals, LLC, a wholly-owned subsidiary of Pfizer Inc. | |||||||||||||
| 7. | SOLE DISPOSITIVE POWER -0- | |||||||||||||
| 8. | SHARED DISPOSITIVE POWER 1,362,499 shares of Common Stock held directly by Anacor Pharmaceuticals LLC, a wholly-owned subsidiary of Pfizer Inc. | |||||||||||||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,362,499* | |||||||||||||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | [ ] | ||||||||||||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.02%** | |||||||||||||
| 12. | TYPE OF REPORTING PERSON CO | |||||||||||||
* Represents 1,362,499 shares held directly by Anacor Pharmaceuticals, LLC. Pfizer Inc. may be deemed to have beneficial ownership over such shares since Anacor Pharmaceuticals, LLC is a wholly-owned subsidiary of Pfizer Inc.
**Based on 19,402,658 shares of Common Stock outstanding as of November 2, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended on September 30, 2022, filed with the SEC on November 9, 2022.
Page 2 of 8
CUSIP No. 037326105
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY) Anacor Pharmaceuticals, LLC 25-1854385 | |||||||||||||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ] (b) [ ] | ||||||||||||
| 3. | SEC USE ONLY | |||||||||||||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||||||||||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER -0- | ||||||||||||
| 6. | SHARED VOTING POWER 1,362,499 shares of Common Stock | |||||||||||||
| 7. | SOLE DISPOSITIVE POWER -0- | |||||||||||||
| 8. | SHARED DISPOSITIVE POWER 1,362,499 Shares of Common Stock | |||||||||||||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,362,499 shares of Common Stock held directly by Anacor Pharmaceuticals, LLC, a wholly-owned subsidiary of Pfizer Inc. | |||||||||||||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | [ ] | ||||||||||||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.02%** | |||||||||||||
| 12. | TYPE OF REPORTING PERSON OO | |||||||||||||
** Based on 19,402,658 shares of Common Stock outstanding as of November 2, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended on September 30, 2022, filed with the SEC on November 9, 2022.
Page 3 of 8
CUSIP No. 037326105
SCHEDULE 13G
| ITEM 1(a) | NAME OF ISSUER: AN2 Therapeutics, Inc. (the “Issuer”). | |||||||
| ITEM 1(b) | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: | |||||||
| 1800 El Camino Real, Suite D, Menlo Park, California 94027 | ||||||||
| ITEM 2(a) | NAME OF PERSON FILING: | |||||||
Pfizer Inc. (“Pfizer”) Anacor Pharmaceuticals, LLC (“Anacor”) Anacor is a wholly-owned subsidiary of Pfizer. The Joint Filing Agreement between Pfizer and Anacor is filed herewith as Exhibit 99.1. | ||||||||
| ITEM 2(b) | ADDRESS OF PRINCIPAL BUSINESS OFFICE: | |||||||
Pfizer and Anacor: 235 East 42nd Street, New York, NY 10017 | ||||||||
| ITEM 2(c) | CITIZENSHIP: | |||||||
| Pfizer and Anacor: Delaware | ||||||||
| ITEM 2(d) | TITLE OF CLASS OF SECURITIES: | |||||||
| Common Stock, $0.00001 par value per share | ||||||||
| ITEM 2(e) | CUSIP NUMBER: 037326105 | |||||||
| ITEM 3 | IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | |||||||
| Not applicable. | ||||||||
(a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78os).
(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
(b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
Page 4 of 8
CUSIP No. 037326105
(f ) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
(g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
(h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
(i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j) A non-US institution, in accordance with §240.13d-1(b)(1)(ii)(J);
(k) Group, in accordance with §230.405 240.13d-1(b)(1)(ii)(K).
If filing as a non-US institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not applicable.
Page 5 of 8
CUSIP No. 037326105
| ITEM 4 | OWNERSHIP: | |||||||||||||||||||
| The information requested in this item is incorporated herein by reference to rows 5 through 11 of the respective cover pages of Pfizer and Anacor to this Schedule 13G. | ||||||||||||||||||||
| ITEM 5 | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: | |||||||||||||||||||
| Not applicable. | ||||||||||||||||||||
| ITEM 6 | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: | |||||||||||||||||||
| Not applicable. | ||||||||||||||||||||
| ITEM 7 | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: | |||||||||||||||||||
| Not applicable. | ||||||||||||||||||||
| ITEM 8 | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: | |||||||||||||||||||
| Not applicable. | ||||||||||||||||||||
| ITEM 9 | NOTICE OF DISSOLUTION OF GROUP: | |||||||||||||||||||
| Not applicable. | ||||||||||||||||||||
| ITEM 10 | CERTIFICATION: | |||||||||||||||||||
| Not applicable. | ||||||||||||||||||||
Page 6 of 8
CUSIP No. 037326105
EXHIBIT INDEX
Exhibit Description
| 99.1 | Joint Filing Agreement, dated as of February 13, 2023, by and between Pfizer and Anacor. | ||||
Page 7 of 8
CUSIP No. 037326105
SIGNATURE
After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2023
| PFIZER INC. | ||||||||
| By: | /s/ Susan Grant | |||||||
| Name: | Susan Grant | |||||||
| Title: | Assistant Secretary | |||||||
| ANACOR PHARMACEUTICALS, LLC | ||||||||
| By: | /s/ Susan Grant | |||||||
| Name: | Susan Grant | |||||||
| Title: | Secretary | |||||||
Page 8 of 8